Clinical trial · Observational
Studying Blood and Tumor Tissue Samples in Women With Invasive Breast Cancer, Ductal or Lobular Carcinoma in Situ, or Benign Breast Disease
Blood Tumor Markers for Molecular Diagnosis of Breast Diseases and Monitoring of Breast Cancer Treatment and Follow-up
NCT00898508CI-TRIAL-00091352completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Collecting and storing samples of blood and tumor tissue from patients with cancer to test in the laboratory may help the study of cancer in the future. PURPOSE: This clinical trial is studying blood and tumor tissue samples in women with invasive breast cancer, ductal carcinoma in situ, lobular carcinoma in situ, or benign breast disease.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (11)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| fluorescent antibody technique | Other | — | UNRESOLVED |
| gene expression analysis | Genetic | — | UNRESOLVED |
| immunohistochemistry staining method | Other | — | UNRESOLVED |
| laboratory biomarker analysis | Other | — | UNRESOLVED |
| liquid chromatography | Other | — | UNRESOLVED |
| mass spectrometry | Other | — | UNRESOLVED |
| medical chart review | Other | — | UNRESOLVED |
| mutation analysis | Genetic | — | UNRESOLVED |
| proteomic profiling |
Design
Arms and outcomes
Arms (2)
- label
- Normal benign breast disease or ductal carcinoma in situ
- interventionNames
- Genetic: gene expression analysis
- Genetic: mutation analysis
- Genetic: proteomic profiling
- Genetic: reverse transcriptase-polymerase chain reaction
- Other: fluorescent antibody technique
- Other: immunohistochemistry staining method
- Other: laboratory biomarker analysis
- Other: liquid chromatography
- Other: mass spectrometry
- Other: medical chart review
- Procedure: quality-of-life assessment
- label
- Invasive breast cancer
- interventionNames
- Genetic: gene expression analysis
- Genetic: mutation analysis
- Genetic: proteomic profiling
- Genetic: reverse transcriptase-polymerase chain reaction
- Other: fluorescent antibody technique
- Other: laboratory biomarker analysis
- Other: liquid chromatography
- Other: mass spectrometry
- Other: medical chart review
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Biopsy-confirmed diagnosis of one of the following:
* Stage I-IV infiltrating ductal or infiltrating lobular carcinoma
* Patients with early-stage disease must not have started systemic treatment; if no systemic treatment is planned, patients must be either preoperative or ≤ 120 days since definitive breast surgery
* Patients with locally advanced disease must be scheduled for neoadjuvant chemotherapy prior to initiation of systemic treatment
* Ductal carcinoma in situ
* Lobular carcinoma in situ
* Benign breast disease
* Proliferative or non-proliferative
* With or without atypia
PATIENT CHARACTERISTICS:
* Karnofsky performance status 50-100%
* Not pregnant
* No prior invasive cancer diagnosis within the past 5 years except for squamous cell or basal cell carcinoma of the skin
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
* No prior systemic therapy (chemotherapy or hormonal therapy) for patients with stage I-III diseaseReferences
Publications (0)
Data not yet available
No reference posted for this study.